title: Diflunisal in osteoarthrosis of the hip and knee.
abstract: Diflunisal (750 mg per day) has been compared with acetylsalicylic acid (ASA) (3000 mg per day) in the treatment of osteoarthrosis of the hip and knee in a double-blind, randomised, multicentre, outpatient study. Thirty-one patients entered the diflunisal group and 29 the ASA group. The response of the 2 groups was comparable, but the incidence of side effects was higher in the ASA group. At the end of the 12-week period more patients in the diflunisal group chose to remain in a further, open study.
mesh_terms: D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D001847:Bone Diseases / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006621:Hip Joint; D006801:Humans; D007592:Joint Diseases / Q000188:drug therapy*; D007719:Knee Joint; D008297:Male; D008875:Middle Aged; D011897:Random Allocation
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001241:Aspirin